Cancer Immunotherapy - Global Market Outlook (2017-2023)

November 2017 | 180 pages | ID: C299866CAC0EN
Stratistics Market Research Consulting

Abstracts

According to Stratistics MRC, the Global Cancer Immunotherapy market is estimated at $62.57 billion in 2016 and is expected to reach $160.24 billion by 2023 growing at a CAGR of 14.3% from 2016 to 2023. Rapid increase in cases of cancer across the globe, technical advancement in treatment therapies, smoking and excessive consumption of alcohol which causes cancer are some of the factors fueling the market growth. High cost for the treatment and lack of awareness are the restraints hampering the market. On the other hand rise in clinical trials against different cancers in immunotherapy and elevated expansion prediction in developing countries are some opportunities for the market over the forecast period.

Based on product, the monoclonal antibodies are made by single clone of cells or cell line and are comprised of identical antibody molecules. The factors such as growing occurrence of cancer and other chronic diseases, rising awareness among patients and rising requirement for personalized medicine are favoring this product’s segment.

In terms of geography, North America captured largest share owing to high mortality rate among cancer patients and government initiative programs to create awareness among the people. Asia Pacific region is expected to be fastest growing during forecast period.

Some of the key players in the market include Bristol-Myers Squibb, F. Hoffmann-LA Roche Ltd, GlaxoSmithKline, Pfizer, Eli Lilly and Company, Janssen Global Services, LLC (Johnson and Johnson), Novartis, Amgen Inc., Biovest International Inc, Ablynx NV, Genentech Inc, Bellicum Pharmaceuticals Inc, Bayer AG, Oxford BioTherapeutics Ltd., Merck, Sydys Corporation, Dendreon, Xencor, Daiichi Sankyo and TG Therapeutics.

Product Types Covered:

• Immune Checkpoint Inhibitors
• Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
• Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1)
• Cancer Monoclonal Antibodies
• Conjugated Monoclonal Antibodies
• Bispecific Monoclonal Antibodies
• Naked Monoclonal Antibodies
• Immunomodulators
• Oncolytic Virus
• Interleukins (IL)
• Interferons (IFN)
• Cancer Vaccines
• Prophylactic Vaccines
• Therapeutic Vaccines
• Cell Therapies
• Chimeric Antigen Receptor (CAR) T Cell Therapy
• Dendritic Cells

Cancer Types Covered:

• Breast Cancer
• Colorectal Cancer
• Head & Neck Cancer
• Multiple Myeloma
• Melanoma
• Lung Cancer
• Prostate Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Other Cancer Types

End Users Covered:

• Hospital
• Clinics
• Other End Users

Regions Covered:

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• U.K.
• Italy
• France
• Spain
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Australia
• New Zealand
• South Korea
• Rest of Asia Pacific
• South America
• Argentina
• Brazil
• Chile
• Rest of South America
• Middle East & Africa
• Saudi Arabia
• UAE
• Qatar
• South Africa
• Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country level segments
• Market share analysis of the top industry players
• Strategic recommendations for the new entrants
• Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
  2.4.1 Data Mining
  2.4.2 Data Analysis
  2.4.3 Data Validation
  2.4.4 Research Approach
2.5 Research Sources
  2.5.1 Primary Research Sources
  2.5.2 Secondary Research Sources
  2.5.3 Assumptions

3 MARKET TREND ANALYSIS

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Futuristic Market Scenario

4 PORTERS FIVE FORCE ANALYSIS

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE

5.1 Introduction
5.2 Immune Checkpoint Inhibitors
  5.2.1 Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
  5.2.2 Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1)
5.3 Cancer Monoclonal Antibodies
  5.3.1 Conjugated Monoclonal Antibodies
  5.3.2 Bispecific Monoclonal Antibodies
  5.3.3 Naked Monoclonal Antibodies
5.4 Immunomodulators
  5.4.1 Oncolytic Virus
    5.4.1.1 Immunity as an Obstacle
    5.4.1.2 Immunotherapy
    5.4.1.3 Approved Products & Clinical Trails
    5.4.1.4 Immunity as an Ally
  5.4.2 Interleukins (IL)
  5.4.3 Interferons (IFN)
5.5 Cancer Vaccines
  5.5.1 Prophylactic Vaccines
  5.5.2 Therapeutic Vaccines
5.6 Cell Therapies
  5.6.1 Chimeric Antigen Receptor (CAR) T Cell Therapy
  5.6.2 Dendritic Cells

6 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY CANCER TYPE

6.1 Introduction
6.2 Breast Cancer
6.3 Colorectal Cancer
6.4 Head & Neck Cancer
6.5 Multiple Myeloma
6.6 Melanoma
6.7 Lung Cancer
6.8 Prostate Cancer
6.9 Ovarian Cancer
6.10 Pancreatic Cancer
6.11 Other Cancer Types

7 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END USER

7.1 Introduction
7.2 Hospital
7.3 Clinics
7.4 Other End Users

8 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY GEOGRAPHY

8.1 Introduction
8.2 North America
  8.2.1 US
  8.2.2 Canada
  8.2.3 Mexico
8.3 Europe
  8.3.1 Germany
  8.3.2 U.K.
  8.3.3 Italy
  8.3.4 France
  8.3.5 Spain
  8.3.6 Rest of Europe
8.4 Asia Pacific
  8.4.1 Japan
  8.4.2 China
  8.4.3 India
  8.4.4 Australia
  8.4.5 New Zealand
  8.4.6 South Korea
  8.4.7 Rest of Asia Pacific
8.5 South America
  8.5.1 Argentina
  8.5.2 Brazil
  8.5.3 Chile
  8.5.4 Rest of South America
8.6 Middle East & Africa
  8.6.1 Saudi Arabia
  8.6.2 UAE
  8.6.3 Qatar
  8.6.4 South Africa
  8.6.5 Rest of Middle East & Africa

9 KEY DEVELOPMENTS

9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 COMPANY PROFILING

10.1 Bristol-Myers Squibb
10.2 F. Hoffmann-LA Roche Ltd
10.3 GlaxoSmithKline
10.4 Pfizer
10.5 Eli Lilly and Company
10.6 Janssen Global Services, LLC (Johnson and Johnson)
10.7 Novartis
10.8 Amgen Inc.
10.9 Biovest International Inc
10.10 Ablynx NV
10.11 Genentech Inc
10.12 Bellicum Pharmaceuticals Inc
10.13 Bayer AG
10.14 Oxford BioTherapeutics Ltd.
10.15 Merck
10.16 Sydys Corporation
10.17 Dendreon
10.18 Xencor
10.19 Daiichi Sankyo
10.20 TG Therapeutics

List Of Tables

LIST OF TABLES

Table 1 Global Cancer Immunotherapy Market Outlook, By Region (2014-2023) ($MN)
Table 2 Global Cancer Immunotherapy Market Outlook, By Product Type (2014-2023) ($MN)
Table 3 Global Cancer Immunotherapy Market Outlook, By Immune Checkpoint Inhibitors (2014-2023) ($MN)
Table 4 Global Cancer Immunotherapy Market Outlook, By Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4) (2014-2023) ($MN)
Table 5 Global Cancer Immunotherapy Market Outlook, By Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) (2014-2023) ($MN)
Table 6 Global Cancer Immunotherapy Market Outlook, By Cancer Monoclonal Antibodies (2014-2023) ($MN)
Table 7 Global Cancer Immunotherapy Market Outlook, By Conjugated Monoclonal Antibodies (2014-2023) ($MN)
Table 8 Global Cancer Immunotherapy Market Outlook, By Bispecific Monoclonal Antibodies (2014-2023) ($MN)
Table 9 Global Cancer Immunotherapy Market Outlook, By Naked Monoclonal Antibodies (2014-2023) ($MN)
Table 10 Global Cancer Immunotherapy Market Outlook, By Immunomodulators (2014-2023) ($MN)
Table 11 Global Cancer Immunotherapy Market Outlook, By Oncolytic Virus (2014-2023) ($MN)
Table 12 Global Cancer Immunotherapy Market Outlook, By Interleukins (IL) (2014-2023) ($MN)
Table 13 Global Cancer Immunotherapy Market Outlook, By Interferons (IFN) (2014-2023) ($MN)
Table 14 Global Cancer Immunotherapy Market Outlook, By Cancer Vaccines (2014-2023) ($MN)
Table 15 Global Cancer Immunotherapy Market Outlook, By Prophylactic Vaccines (2014-2023) ($MN)
Table 16 Global Cancer Immunotherapy Market Outlook, By Therapeutic Vaccines (2014-2023) ($MN)
Table 17 Global Cancer Immunotherapy Market Outlook, By Cell Therapies (2014-2023) ($MN)
Table 18 Global Cancer Immunotherapy Market Outlook, By Chimeric Antigen Receptor (CAR) T Cell Therapy (2014-2023) ($MN)
Table 19 Global Cancer Immunotherapy Market Outlook, By Dendritic Cells (2014-2023) ($MN)
Table 20 Global Cancer Immunotherapy Market Outlook, By Cancer Type (2014-2023) ($MN)
Table 21 Global Cancer Immunotherapy Market Outlook, By Breast Cancer (2014-2023) ($MN)
Table 22 Global Cancer Immunotherapy Market Outlook, By Colorectal Cancer (2014-2023) ($MN)
Table 23 Global Cancer Immunotherapy Market Outlook, By Head & Neck Cancer (2014-2023) ($MN)
Table 24 Global Cancer Immunotherapy Market Outlook, By Multiple Myeloma (2014-2023) ($MN)
Table 25 Global Cancer Immunotherapy Market Outlook, By Melanoma (2014-2023) ($MN)
Table 26 Global Cancer Immunotherapy Market Outlook, By Lung Cancer (2014-2023) ($MN)
Table 27 Global Cancer Immunotherapy Market Outlook, By Prostate Cancer (2014-2023) ($MN)
Table 28 Global Cancer Immunotherapy Market Outlook, By Ovarian Cancer (2014-2023) ($MN)
Table 29 Global Cancer Immunotherapy Market Outlook, By Pancreatic Cancer (2014-2023) ($MN)
Table 30 Global Cancer Immunotherapy Market Outlook, By Other Cancer Types (2014-2023) ($MN)
Table 31 Global Cancer Immunotherapy Market Outlook, By End User (2014-2023) ($MN)
Table 32 Global Cancer Immunotherapy Market Outlook, By Hospital (2014-2023) ($MN)
Table 33 Global Cancer Immunotherapy Market Outlook, By Clinics (2014-2023) ($MN)
Table 34 Global Cancer Immunotherapy Market Outlook, By Other End Users (2014-2023) ($MN)

Note: Tables for North America, Europe, APAC, South America and Middle East & Africa Regions are also represented in the same manner as above